Accendra Health Earnings Call Transcripts
Fiscal Year 2026
-
The meeting approved all four proposals, including director elections and incentive plan. The company highlighted its transition to a pure play home-based care provider, serving most of the U.S. with a streamlined workforce and strong brand presence.
-
First quarter 2026 results met expectations, with revenue down 6.8% year-over-year but up 1% excluding a major payer exit. Gross margins nearly doubled post-divestiture, and a comprehensive balance sheet optimization will reduce debt and extend maturities.
Fiscal Year 2025
-
Revenue grew over 3% in 2025 to nearly $2.8B, with strong performance in sleep, ostomy, and urology. 2026 guidance reflects a $300M revenue headwind from a major payer loss, but cost reductions and technology investments are expected to support margins and cash flow.
-
Announced sale of Products and Healthcare Services segment, shifting focus to higher-margin Patient Direct home-based care. Q3 revenue grew modestly, with strong performance in sleep therapy and ostomy, while guidance for 2025 was affirmed. Free cash flow and margins are expected to improve post-divestiture.
-
Q2 2025 saw 3.3% revenue growth and margin expansion, with Patient Direct driving results amid the P&HS divestiture. Guidance for 2025 is $2.76–$2.82B revenue and $376–$382M adjusted EBITDA, with all divestiture proceeds to reduce debt.
-
Q1 2025 saw mid-single digit revenue growth and 31% operating income growth in patient direct, with strong performance across therapy categories. Tariff exposure of $100–$150 million is being addressed through targeted price increases, and guidance for 2025 is reaffirmed.
Fiscal Year 2024
-
Mid-single-digit revenue growth and 13% adjusted EPS growth were achieved in 2024, with strong patient-direct performance and significant debt reduction. 2025 guidance anticipates continued growth, a $100 million share repurchase, and the Rotech acquisition, while the P&HS segment sale process advances.
-
Q3 2024 delivered 5% revenue growth, margin expansion, and significant debt reduction, despite hurricane-related disruptions and ongoing patient eligibility backlogs. Guidance for 2024 was refined, with strong momentum expected into 2025 and a strategic advantage anticipated from upcoming industry tariffs.
-
Q2 revenue grew 4% year-over-year to $2.7B, with both segments contributing and profitability improving. The Rotech acquisition will expand Patient Direct, and strong cash flow is expected in H2, supporting reaffirmed 2024 guidance.
-
The acquisition of Rotech for $1.36 billion in cash will expand the Patient Direct segment, diversify the product and payer mix, and accelerate growth toward a $5 billion revenue target by 2028. Management expects $50 million in synergies by year three, with the deal accretive to margins and EPS from year two.